A Phase 1B Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Adenoviral Subtype 35 (rAd35) and Subtype 5 (rAd5) HIV-1 Vaccines When Given as a Heterologous Prime-boost Regimen or as Boosts to a Recombinant DNA Vaccine in Healthy, Ad5-Naive and Ad5-Exposed, Low Risk, HIV-1 Uninfected Adult Participants

Trial Profile

A Phase 1B Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Adenoviral Subtype 35 (rAd35) and Subtype 5 (rAd5) HIV-1 Vaccines When Given as a Heterologous Prime-boost Regimen or as Boosts to a Recombinant DNA Vaccine in Healthy, Ad5-Naive and Ad5-Exposed, Low Risk, HIV-1 Uninfected Adult Participants

Completed
Phase of Trial: Phase I

Latest Information Update: 18 May 2015

At a glance

  • Drugs VRC-HIVADV027-00-VP (Primary) ; VRC-HIVADV038-00-VP (Primary) ; VRC-HIVDNA044-00-VP (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 07 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 23 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 20 May 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top